Relmada Therapeutics, Inc. (RLMD) NASDAQ
6.42
-0.43(-6.28%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
6.42
-0.43(-6.28%)
Currency In USD
Address
2222 Ponce de Leon Boulevard
Coral Gables, FL 33134
United States of America (the)
Phone
786 629 1376
Website
Sector
Healthcare
Industry
Biotechnology
Employees
17
First IPO Date
June 20, 2014
| Name | Title | Pay | Year Born |
| Sergio Traversa | Chief Executive Officer & Director | 3.94M | 1960 |
| Paul E. Kelly | Chief Operating Officer & Director | 1.96M | 1957 |
| Charles S. Ence | Chief Accounting & Compliance Officer | 2.17M | 1965 |
| Maged S. Shenouda | Chief Financial Officer | 2.64M | 1964 |
| Andrew Cutler | Senior Clinical Development Advisor | 0 | N/A |
| Raj S. Pruthi | Chief Medical Officer of Urology | 0 | 1967 |
| Richard Mangano | Consultant | 0 | 1950 |
| Gina DiGuglielmo | Vice President & Head of Clinical Operations | 0 | N/A |
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.